EBS vs. BOLT, RGLS, FBIO, RIGL, VNDA, VSTM, XOMA, PDSB, IOBT, and RNAC
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include Bolt Biotherapeutics (BOLT), Regulus Therapeutics (RGLS), Fortress Biotech (FBIO), Rigel Pharmaceuticals (RIGL), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), XOMA (XOMA), PDS Biotechnology (PDSB), IO Biotech (IOBT), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical preparations" industry.
Emergent BioSolutions (NYSE:EBS) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.
78.4% of Emergent BioSolutions shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 1.2% of Emergent BioSolutions shares are held by insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Emergent BioSolutions has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500.
In the previous week, Emergent BioSolutions had 2 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 4 mentions for Emergent BioSolutions and 2 mentions for Bolt Biotherapeutics. Emergent BioSolutions' average media sentiment score of 0.20 beat Bolt Biotherapeutics' score of -0.16 indicating that Emergent BioSolutions is being referred to more favorably in the media.
Emergent BioSolutions received 332 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. However, 68.38% of users gave Bolt Biotherapeutics an outperform vote while only 66.45% of users gave Emergent BioSolutions an outperform vote.
Bolt Biotherapeutics has lower revenue, but higher earnings than Emergent BioSolutions. Bolt Biotherapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
Emergent BioSolutions has a net margin of -72.11% compared to Bolt Biotherapeutics' net margin of -878.58%. Emergent BioSolutions' return on equity of -37.35% beat Bolt Biotherapeutics' return on equity.
Emergent BioSolutions currently has a consensus price target of $5.00, indicating a potential upside of 157.73%. Bolt Biotherapeutics has a consensus price target of $7.00, indicating a potential upside of 494.28%. Given Bolt Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Bolt Biotherapeutics is more favorable than Emergent BioSolutions.
Summary
Emergent BioSolutions and Bolt Biotherapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
